Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide

This study has been completed.
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Jeffrey Raizer, Northwestern University
ClinicalTrials.gov Identifier:
NCT00990652
First received: October 6, 2009
Last updated: December 11, 2013
Last verified: December 2013
  Purpose

Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bortezomib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving bortezomib together with temozolomide after surgery may kill any tumor cells that remain after surgery.

This phase II trial is studying how well giving bortezomib before surgery followed by giving bortezomib together with temozolomide after surgery works in treating patients with recurrent malignant glioma.


Condition Intervention Phase
Brain and Central Nervous System Tumors
Drug: Bortezomib
Drug: Temozolomide
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial Evaluating the Effects of Bortezomib in Patients With Recurrent Malignant Gliomas Treated Prior to Surgery and Then Bortezomib and Temozolomide Post-operatively

Resource links provided by NLM:


Further study details as provided by Northwestern University:

Primary Outcome Measures:
  • Number of Patients Surviving Without Disease Progression After 6 Months [ Time Frame: From date of first treatment until disease progression, death, or early discontinuation of treatment (up to 24 months) ] [ Designated as safety issue: No ]

    Patients will be monitored from date of first treatment to the date of first observation of progressive disease, non-reversible neurologic progression or increasing steroid requirements, death due to any cause, or early discontinuation of treatment. Progression-free survival will be defined as the absence of any of the above after 6 months.

    Progression (defined by MacDonald Criteria) is a 25% increase in the sum of products of all measurable lesions over smallest sum observed compared to baseline, OR clear worsening of any evaluable disease, OR appearance of any new lesion/site, OR failure to return for evaluation due to death or deteriorating condition (unless clearly unrelated to the cancer).



Secondary Outcome Measures:
  • Number of Participants Achieving a Response to Treatment (Either Complete or Partial Response) as Defined by MacDonald Criteria [ Time Frame: Day of treatment post-surgery and then approximately every 8 weeks thereafter until off treatment ] [ Designated as safety issue: No ]

    This measure was assessed only in patients who had residual tumor post-operatively. Per MacDonald Criteria:

    Complete Response requires complete disappearance of all measurable & evaluable disease, no new lesions, no evidence of non-evaluable disease, and only minimal or no use of steroids.

    Partial Response is defined as >= 50% decrease compared to baseline in the sum of products of perpendicular diameters of all measurable lesions, no progression of evaluable disease, and no new lesions. Responders must be on the same or decreasing doses of steroid.

    Response was assessed by imaging (MRI or CT with contrast).


  • Number of Grade 1, 2, 3, 4, and 5 Adverse Events Observed During Study Treatment (Defined by CTCAE v 3.0) [ Time Frame: Days 1, 4, 8 pre-surgery, and then at the start of every cycle (approximately every 4 weeks) post-surgery while on treatment ] [ Designated as safety issue: Yes ]

    Adverse events (AEs) were graded according to the National Cancer Institute's Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0. In general, AEs are graded according to the following:

    Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE


  • Overall Survival (in Days) [ Time Frame: Days 1, 4, 8 pre-surgery, once per cycle (every 4 weeks) while on treatment post-surgery, and then every 3 months up to 2 years during follow-up ] [ Designated as safety issue: No ]
  • Overall Survival Rate at 6 Months [ Time Frame: After 6 months on study ] [ Designated as safety issue: No ]
    The rate of overall survival at 6 months (regardless of disease progression) was calculated.


Other Outcome Measures:
  • Correlation of Expression of NFKBIA Gene With Response to Therapy and Survival. [ Time Frame: Tissue samples for analysis were obtained on the day of surgery for all patients ] [ Designated as safety issue: No ]
    The effects of bortezomib on the endogenous modulators of NF-Kappa B pathways, especially the NFKBIA gene (nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha) were assessed using novel assay technology; expression of NFKBIA was then correlated with response to therapy and patient survival.

  • Change in MGMT Methylation Status as Well as Other Methylation Patterns in Plasma [ Time Frame: Blood samples drawn on days 1, 4, and 8 pre-surgery, and then prior to cycle 1 and every 2 cycles thereafter ] [ Designated as safety issue: No ]
    To determine MGMT methylation status as well as other methylation patterns in plasma

  • Pharmacokinetics of Bortezomib in Tumor Tissue Taken at the Time of Surgery. [ Time Frame: Tissue sample taken at the time of surgery for all patients. ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: May 2009
Study Completion Date: October 2012
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Bortezomib + Temozolomide
Patients receive an injection of bortezomib 1.7mg/m^2 on days 1, 4 and 8. Patients then undergo their standard of care surgery on day 8 or 9 to remove the tumor. Once recovered from surgery, patients receive combination treatment with temozolomide and bortezomib in periods called cycles (1 cycle = 28 days). Temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle, and bortezomib injections are given on days 7 and 21 of each cycle.
Drug: Bortezomib
Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
Other Name: Velcade
Drug: Temozolomide
After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
Other Name: Temodar

Detailed Description:

Patients receive bortezomib IV on days 1, 4, and 8. Patients then undergo surgical resection of the tumor on day 8 or 9.

Beginning approximately 14 days after surgery, patients receive oral temozolomide on days 1-7 and 14-21 and bortezomib IV on days 7 and 21. Treatment repeats every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity.

Tumor tissue and blood samples are collected periodically for biomarker analysis, gene methylation studies, and pharmacokinetic studies.

After completion of study therapy, patients are followed up every 3 months for 2 years.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed malignant glioma, including any of the following subtypes:

    • Glioblastoma multiforme
    • Gliosarcoma
    • Anaplastic astrocytoma
    • Anaplastic oligodendroglioma
    • Anaplastic mixed oligoastrocytoma
    • Malignant astrocytoma not otherwise specified
  • Must show unequivocal evidence of tumor recurrence or progression by MRI or CT scan with contrast
  • Candidate for surgery AND requires surgery

    • Evaluable or measurable disease following resection of recurrent tumor is not required
  • Failed prior standard radiotherapy and temozolomide

    • Patients who have undergone stereotactic radiosurgery must have confirmation of true progressive disease (rather than radiation necrosis) by PET scan, magnetic resonance spectroscopy (MRS), or magnetic resonance perfusion (MRP) prior to surgery
    • Patients with lower-grade gliomas that have undergone radiographic malignant transformation allowed provided they failed radiotherapy (with or without temozolomide) and require surgery
  • Life expectancy > 12 weeks

Exclusion Criteria:

  • Not pregnant or nursing
  • Negative pregnancy test
  • No other medical issues (e.g., bleeding, infection, HIV, or serious medical or psychiatric illness) that would preclude study therapy
  • Myocardial infarction within the past 6 months
  • No other active cancer(s) except non-melanoma skin cancer or carcinoma in situ of the cervix, unless in complete remission and off of all therapy for that cancer for ≥ 3 years
  • No hypersensitivity to bortezomib, boron, or mannitol
  • More than 4 weeks since prior radiotherapy
  • At least 4 weeks since prior cytotoxic therapy (6 weeks for nitrosoureas)
  • At least 3 weeks since prior investigational drugs
  • At least 2 weeks since prior enzyme-inducing anticonvulsants
  • Concurrent non-enzyme-inducing anticonvulsants allowed
  • No other concurrent standard or investigational anticancer treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00990652

Locations
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
Northwestern University
Millennium Pharmaceuticals, Inc.
Investigators
Principal Investigator: Jeffrey Raizer, MD Northwestern University
  More Information

No publications provided

Responsible Party: Jeffrey Raizer, Jeffrey Raizer, MD, Northwestern University
ClinicalTrials.gov Identifier: NCT00990652     History of Changes
Other Study ID Numbers: NU 08C5, STU00008280
Study First Received: October 6, 2009
Results First Received: December 11, 2013
Last Updated: December 11, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Northwestern University:
brain tumor

Additional relevant MeSH terms:
Central Nervous System Neoplasms
Nervous System Neoplasms
Neoplasms
Neoplasms by Site
Nervous System Diseases
Bortezomib
Dacarbazine
Temozolomide
Alkylating Agents
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014